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 Interleukin-1 receptor 8 (IL-1R8, also known as single immunoglobulin IL-1R-related 31	  
receptor, SIGIRR, or TIR8) is a member of the IL-1 receptor (ILR) family with distinct 32	  
structural and functional characteristics, acting as a negative regulator of ILR and Toll-like 33	  
receptor (TLR) downstream signaling pathways and inflammation1. NK cells are innate 34	  
lymphoid cells which mediate resistance against pathogens and contribute to the activation 35	  
and orientation of adaptive immune responses2-4. NK cells mediate resistance against 36	  
hematopoietic neoplasms but are generally considered to play a minor role in solid tumor 37	  
carcinogenesis5-7. Here we report that IL-1R8 serves as a checkpoint for NK cell maturation 38	  
and effector function. Its genetic blockade unleashes NK-cell mediated resistance to hepatic 39	  
carcinogenesis, hematogenous liver and lung metastasis and cytomegalovirus infection.  40	  
Several lines of evidence suggest that IL-1R8 interferes with the association of TIR module-41	  
containing adaptor molecules with signaling receptor complexes of the ILR or TLR family, tuning 42	  
downstream signaling, thus negatively controlling inflammatory and immune responses and T 43	  
helper (TH) cell polarization and functions1,8. Moreover, IL-1R8 is the co-receptor of IL-1R5/IL-44	  
18Rα for IL-37, and is required for the anti-inflammatory activity of this human cytokine9. 45	  
Deregulated activation by ILR or TLR ligands in IL-1R8-deficient mice has been associated with 46	  
exacerbated inflammation and immunopathology, including selected cancers, or autoimmune 47	  
diseases10. 48	  
 IL-1R8 is widely expressed10. However, we found strikingly high levels of IL-1R8 mRNA 49	  
and protein in human NK cells, compared to other circulating leukocytes and monocyte-derived 50	  
macrophages (Fig. 1a, Extended Data Fig. 1a). IL1R8 mRNA levels increased during NK cell 51	  
maturation11 (Extended Data Fig. 1b) and surface protein expression mirrored transcript levels (Fig. 52	  
1b, Extended Data Fig. 1c). IL-1R8 expression was detected at low level in bone marrow 53	  
pluripotent haematopoietic stem cells and NK cell precursors and was selectively upregulated in 54	  
mature NK cells and not in CD3+ lymphocytes (Extended Data Fig. 1d).  55	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  Murine NK cells expressed significantly higher levels of Il1r8 mRNA, compared to other 56	  
leukocytes (Fig. 1c) and relative to other ILRs (Extended Data Fig. 1e, 1f). In line with the results 57	  
obtained in human NK cells, Il1r8 mRNA level increased during the 4-stage developmental 58	  
transition from CD11blowCD27low to CD11bhighCD27low12 (Fig. 1d, Extended Data Fig. 1g).  59	  
 To assess the role of IL-1R8 in NK cells, we took advantage of IL-1R8-deficient mice. 60	  
Among CD45+ cells, the NK cell frequency and absolute numbers were significantly higher in 61	  
peripheral blood of Il1r8-/- compared to Il1r8+/+ mice and slightly increased in liver and spleen. 62	  
(Fig. 2a, 2b). In addition, the frequency of the CD11b high CD27low and KLRG1+ mature subset was 63	  
significantly higher in Il1r8-/- mice compared to Il1r8+/+ mice in BM, spleen and blood, indicating a 64	  
more mature phenotype of NK cells13 (Fig. 2c, 2d, Extended Data Fig. 2a, 2b).   65	  
 The enhanced NK cell maturation in Il1r8-/- mice occurred already at 2 and 3 weeks of age, 66	  
whereas the frequency of NK precursors was similar in Il1r8-/- and Il1r8+/+ BM, indicating that IL-67	  
1R8 regulated early events in NK cell differentiation, but did not affect the development of NK cell 68	  
precursors (Extended Data Fig. 2c-e)12. 69	  
 We next investigated whether IL-1R8 impacted on NK cell function. The expression of the 70	  
activating receptors NKG2D, DNAM-1 and Ly49H was significantly upregulated in peripheral 71	  
blood Il1r8-/- NK cells (Extended Data Fig. 2f). IFNγ and Granzyme B production and FasL 72	  
expression were more sustained in IL-1R8-deficient NK cells upon ex-vivo stimulation in the 73	  
presence of IL-18 (Fig. 2e-g, Extended Data Fig. 2g). The frequency of IFNγ+ NK cells was higher 74	  
in Il1r8-/- total NK cells and in all NK cell subsets. Thus, IFNγ production was enhanced 75	  
independently of the NK cell maturation state. Analysis of competitive bone marrow chimeras 76	  
revealed that IL-1R8 regulates NK cell differentiation in a cell-autonomous way (Extended Data 77	  
Fig. 2h-k). Along the same line, co-culture experiments of NK cells with LPS- or CpG-primed 78	  
dendritic cells (DCs) showed that Il1r8-/- NK cells produced higher IFNγ levels irrespectively of the 79	  
DC genotype (Extended Data Fig. 2l). 80	  
 IL-18 is a member of the IL-1 family, which plays an important role in NK cell 81	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differentiation and function1,14. Enhanced NK cell maturation and effector function in Il1r8-/- mice 82	  
was abolished by IL-18 blockade or genetic deficiency but unaffected by IL-1R1-deficiency (Fig. 83	  
2h, 2i, Extended Data Fig. 3a, 3b). Cohousing and antibiotic treatment had no impact, thus 84	  
excluding a role of microbiota15 in the phenotype of Il1r8-/- mice (Extended Data Fig. 3c, 3d).  85	  
 The results reported above suggested that IL-1R8 regulated the IL-18 signaling pathway in 86	  
NK cells and indeed, increased phospho-IRAK4/IRAK4 ratio was induced by IL-18 in Il1r8-/- NK 87	  
cells compared to wild type NK cells, indicating unleashed early signaling downstream of MyD88 88	  
and myddosome formation (Fig. 2j), consistently with the proposed molecular mode of action of IL-89	  
1R81,9,16. Indeed, by stimulated emission depletion (STED) microscopy, we observed clustering of 90	  
IL-1R8 and IL-18Rα (Extended Data Fig. 3e), in line with previous studies9. IL-1R8-deficiency 91	  
also led to enhanced IL-18-dependent phosphorylation of S6 and JNK in NK cells, suggesting that 92	  
IL-1R8 inhibited IL-18-dependent activation of the mTOR and JNK pathways (Fig. 2j), which 93	  
control NK cell metabolism, differentiation and activation17,18. 94	  
 To obtain a deeper insight into the impact of IL-1R8 deficiency on NK cell function and on 95	  
the response to IL-18, RNA-seq analysis was conducted. IL-1R8 deficiency had a profound impact 96	  
on the resting transcriptional profile of NK cells and on top on responsiveness to IL-18 (Fig. 2k, 97	  
Extended Data Fig. 4a and Table 1). The profile of IL-1R8 deficient cells includes activation 98	  
pathways (e.g. MAPK), adhesion molecules involved in cell-to-cell interactions and cytotoxicity 99	  
(ICAM-1), and increased production of selected chemokines (CCL4). The latter may represent an 100	  
NK cell based amplification loop of leukocyte recruitment, including NK cells themselves. 101	  
 To investigate the role of IL-1R8 in human NK cells (Fig. 1a, 1b), we first retrospectively 102	  
analyzed its expression in relation to responsiveness to a combination of IL-18 and IL-12 in normal 103	  
donors. We observed an inverse correlation between IL-1R8 levels and IFNγ production by 104	  
peripheral blood NK cells (r2=0.7969, p=0.0012) (Fig. 2l). In addition, IL-1R8 partial silencing in 105	  
peripheral blood NK cells with small interfering RNA (siRNA) was associated with a significant 106	  
increase in IFNγ production (Fig. 2m) and upregulation of CD69 expression (not shown). These 107	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results suggest that in human NK cells as in murine counterparts IL-1R8 serves as a negative 108	  
regulator of activation and that its inactivation unleashes human NK cell effector function. 109	  
In an effort to assess the actual relevance of IL-1R8-mediated regulation of NK cells, 110	  
anticancer and antiviral resistance were examined. The liver is characterized by a high frequency of 111	  
NK cells19. Therefore we focused on liver carcinogenesis. In a model of diethylnitrosamine (DEN)-112	  
induced hepatocellular carcinoma (HCC), IL-1R8-deficient male and female mice20 were protected 113	  
against the development of lesions, in terms of macroscopic number, size (Fig. 3a, Extended Data 114	  
Fig. 5a, 5b) and histology (not shown). The percentage and absolute number of NK cells, and the 115	  
percentage of IFNγ+ NK cells were higher in Il1r8-/- HCC-bearing mice (Fig. 3b, 3c, Extended Data 116	  
Fig. 5c). Finally, increased levels of cytokines involved in anti-tumor immunity (e.g. IFNγ) and a 117	  
reduction of pro-inflammatory cytokines associated with tumor promotion (IL-6, TNFα, IL-1β, 118	  
CCL2, CXCL1) were observed (Extended Data, Table 2). Most importantly, the depletion of NK 119	  
cells abolished the protection against liver carcinogenesis observed in Il1r8-/- mice (Fig. 3d and 120	  
Extended Data Fig. 5d).  121	  
 Evidence suggests that NK cells can inhibit hematogenous cancer metastasis5. In a model of 122	  
sarcoma (MN/MCA1) spontaneous lung metastasis, Il1r8-/- mice showed a reduced number of 123	  
hematogenous metastasis, whereas primary tumor growth was unaffected (Fig. 3e, Extended Data 124	  
Fig. 5e, 5f). The frequency of total and mature CD27low NK cells was higher in Il1r8-/- lungs (Fig. 125	  
3f and not shown). Assessment of lung metastasis at sacrifice and in vivo imaging analysis (Fig. 3g, 126	  
Extended Data Fig. 5e) showed that the protection was completely abolished in NK cell-depleted 127	  
Il1r8-/- mice. In addition, IL-18 or IFNγ neutralization abolished or dramatically reduced the 128	  
protection against metastasis observed in Il1r8-/- mice (Extended Data Fig. 5g).	   In contrast, 129	  
depletion of CD4+/CD8+ cells or IL-17A, or deficiency of IL-1R1 (involved in TH17 development), 130	  
did not affect the phenotype (Extended Data Fig. 5h, 5i).  131	  
 Liver metastasis is a major problem in the progression of colorectal cancer. We therefore 132	  
assessed the potential of Il1r8-/- NK cells to protect against liver metastasis using the MC38 colon 133	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carcinoma line21. As shown in Fig. 3h, Il1r8-/- mice were protected against MC38 colon carcinoma 134	  
liver metastasis. In addition, IL-18 genetic deficiency abrogated the protection against liver 135	  
metastasis observed in Il1r8-/- mice (Extended Data Fig. 5j), thus indicating that the IL-1R8-136	  
dependent control of MC38-derived liver metastasis occurs through the IL-18/IL-18R axis. To 137	  
assess the primary role of Il1r8-/- NK cells in the cancer protection, adoptive transfer was used 138	  
(Extended Data Fig. 5k-m). Adoptive transfer of Il1r8+/+ NK cells had no effect on lung and liver 139	  
metastasis. In contrast, adoptive transfer of Il1r8-/- NK cells significantly and dramatically reduced 140	  
the number and volume of lung and liver metastasis (Fig. 3i, 3j, Extended Data Fig. 5n). Given the 141	  
natural history and clinical challenges of colorectal cancer, this observation has potential 142	  
translational implications. Thus, IL-1R8 genetic inactivation unleashes NK cell mediated resistance 143	  
to carcinogenesis in the liver and amplifies the anti-metastatic potential of these cells in liver and 144	  
lung in a NK cell-autonomous manner.  145	  
 Finally we investigated whether IL-1R8 impacts on NK cell antiviral activity, focusing on 146	  
murine cytomegalovirus (MCMV) infection22. As shown in Fig. 4a, liver viral titers were lower in 147	  
Il1r8-/- compared to Il1r8+/+ mice, indicating that IL-1R8-deficiency was associated with a more 148	  
efficient control of MCMV infection. The frequency of IFNγ+ NK cells and degranulation (i.e. 149	  
frequency of CD107a+ NK cells) were significantly higher in the spleen and liver of Il1r8-/- mice on 150	  
day 1.5 post infection (Fig. 4b). On day 4.5 post infection, IFNγ+ and CD107a+ NK cells were 151	  
strongly reduced, in both spleen and liver, as a consequence of better control of viral spread (Fig. 152	  
4b). Consistently with a more efficient control of the infection, reduced levels of pro-inflammatory 153	  
cytokines were observed in Il1r8-/- mice (Extended Data Fig. 6a). NK cell adoptive transfer 154	  
experiments were performed in MCMV infected newborn mice that still do not have mature NK 155	  
cells12. As shown in Fig. 4c, the adoptive transfer of Il1r8-/- NK cells conferred higher protection 156	  
compared to Il1r8+/+ NK cells, with for instance 4 out of 9 mice having no detectable virus titer in 157	  
the brain.  158	  
 NK cells belong to the complex, diverse realm of innate lymphoid cells23.  Human and 159	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murine non-NK ILCs express IL-1R8 mRNA and protein24 (and our unpublished data; Camilla 160	  
Jandus, personal communication).  Preliminary experiments were conducted in an effort to assess 161	  
the role of IL-1R8 in ILC function. In the MCMV infection model, Il1r8-/- ILC1 showed increased 162	  
IFNγ production, but represented a minor population compared to NK cells and 1/30 of Il1r8-/- IFNγ 163	  
producing cells (Fig. 4d) and therefore are unlikely to play a significant role in the phenotype. 164	  
These results provide initial evidence that IL-1R8 has a regulatory function in ILCs. Further studies 165	  
are required to assess its actual significance in ILC diverse populations. Collectively, these results 166	  
indicate that IL-1R8-deficient mice were protected against MCMV infection and that protection 167	  
was dependent on increased NK cell activation.  168	  
 IL-1R8 deficiency was associated with exacerbated inflammatory and immune reactions 169	  
under a variety of conditions1,10. NK cells engage in bidirectional interactions with macrophages, 170	  
dendritic cells and other lymphocytes3,4,25,26. Therefore the role of NK cells in inflammatory and 171	  
autoimmune conditions associated with IL-1R8 deficiency1,10 will need to be examined. IL-1R8 172	  
deficient mice show increased susceptibility to colitis and colitis-associated azoxymethane (AOM) 173	  
carcinogenesis27,28. The divergent impact on carcinogenesis of IL-1R8 deficiency in the intestine 174	  
and liver is likely to reflect fundamental, tissue-dictated differences of immune mechanisms 175	  
involved in carcinogenesis in these different anatomical sites. In particular, high numbers of NK 176	  
cells are present in the liver19 and this physiological characteristic of this organ is likely to underlie 177	  
this apparent divergence.  178	  
 NK cells are generally not credited to play a major role in the control of solid tumors6. 179	  
Conversely there is evidence for a role of NK cells in the control of hematogenous lung 180	  
metastasis5,29. The results presented here show that unleashing NK cells by genetic inactivation of 181	  
IL-1R8 resulted in inhibition of liver carcinogenesis and protection against liver and lung 182	  
metastasis. IL-1R8-deficient mice show exacerbated TLR and IL-1-driven inflammation10 and 183	  
inflammation promotes liver carcinogenesis30. Therefore the results presented here are likely an 184	  
underestimate of the potential against liver primary and metastatic tumors of removal of the NK cell 185	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checkpoint IL-1R8. Therefore, NK cells have the potential to restrain solid cancer and metastasis, 186	  
provided critical, validated checkpoints such as IL-1R8 are removed and the tissue immunological 187	  
landscape is taken into account. 188	  
  189	  
 190	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Figures  275	  
Figure 1. Expression of IL-1R8 in human and murine NK cells 276	  
(a, b) IL-1R8 protein expression in human primary NK cells and other leukocytes (a) and NK cell 277	  
maturation stages (b). 278	  
(c, d) Il-1r8 mRNA expression in murine primary NK cells and other leukocytes (c) and in sorted 279	  
splenic NK cell subsets (c).  280	  
*p < 0.05, **p < 0.01, ***p < 0.001 One-way ANOVA. Mean ± SEM.  281	  
 282	  
Figure 2. NK cell differentiation and function in IL-1R8-deficient mice 283	  
(a, b) NK cell frequency and absolute number among leukocytes in Il1r8+/+ and Il1r8-/- mice.  284	  
(c, d) NK cell subsets (c) and KLRG1+ NK cells (d).  285	  
 (e-g) IFNγ (e), Granzyme B (f) and FasL (g) expression in stimulated NK cells.  286	  
(h) Splenic CD27low NK cell frequency upon IL-18 in vivo depletion.  287	  
(i) IFNγ production by Il1r8+/+ and Il1r8-/- NK cells upon co-culture with CpG-primed Il1r8+/+ DCs 288	  
and IL-18 blockade. 289	  
(j) IRAK4, S6 and JNK phosphorylation in NK cells upon stimulation with IL-18. 290	  
(k) RNA-seq analysis of resting and IL-18-activated NK cells. Differentially expressed (p<0.05) 291	  
genes are shown. FC: fold change.  292	  
(l) Correlation between IL-1R8 expression and IFNγ production in human peripheral blood NK 293	  
cells.  294	  
(m) IL-1R8 expression and IFNγ production in human NK cells 7 days after transfection with 295	  
control siRNA or IL-1R8-specific siRNA in duplicate. 296	  
(a-l) *p < 0.05, **p < 0.01, ***p < 0.001 between selected relevant comparisons, two-tailed 297	  
unpaired Student’s t test, or ANOVA; (k) r: Pearson correlation coefficient; Mean ± SEM.  298	  
 299	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Figure 3. NK cell-mediated protection against liver carcinogenesis and metastasis in IL-1R8-300	  
deficient mice  301	  
(a) Macroscopic score of liver lesions in male Il1r8+/+ and Il1r8-/- mice 6, 8, 10 and 12 months after 302	  
DEN injection.  303	  
(b) Frequency and representative histological quantification of NK cell infiltrate in liver of tumor 304	  
bearing mice. (20X, bar = 100µm). 305	  
(c) Frequency of IFNγ+ NK cells in liver of tumor bearing mice. 306	  
(d) Macroscopic score of liver lesions in male mice upon NK cell depletion.  307	  
(e) Number of spontaneous lung metastasis.  308	  
(f) NK cell frequency in the lungs of MN/MCA1 tumor bearing mice. 309	  
(g) Number of lung metastasis in MN/MCA1 tumor bearing mice upon NK cell depletion.  310	  
(h) Number of liver metastasis in MC38 colon carcinoma bearing mice. 311	  
(i,j) Number of lung (i) and liver (j) metastasis of Il1r8+/+ mice after adoptive transfer of Il1r8+/+ 312	  
and Il1r8-/- NK cells. 313	  
(a, d) Representative images of female livers are shown.  314	  
(a-j) *p < 0.05, **p < 0.01, ***p < 0.001 between selected relevant comparisons, two-tailed 315	  
unpaired Student’s t test or Mann-Whitney test. Mean ± SEM.  316	  
 317	  
Figure 4. NK cell-mediated antiviral resistance in IL-1R8-deficient mice 318	  
(a) Viral titer in livers of Il1r8+/+ and Il1r8-/- infected mice. 319	  
(b) Frequency of IFNγ+ and CD107a+ NK cells of infected mice. 320	  
 (c) Viral titers in newborn wild type mice upon adoptive transfer of Il1r8+/+ and Il1r8-/- NK cells (7 321	  
days post infection). 322	  
(d) Frequency of IFNγ + cells in the liver of MCMV infected mice.  323	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 (a-d) *p < 0.05, **p < 0.01, ***p < 0.001, two-tailed Mann-Whitney test (a, c) or unpaired 324	  
Student’s t test (b, d). Median (a, c). Mean ± SEM (b, d). DL: detection limit. Day p.i.: day post 325	  
infection. 326	  
  327	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Methods 328	  
Animals. All female and male mice used were on a C57BL/6J genetic background and 8-12 weeks-329	  
old, unless specified. Wild-type mice were obtained from Charles River Laboratories, Calco, Italy 330	  
or were littermates of Il1r8-/- mice. IL-1R8-deficient mice were generated as described31. Il1r1-/- 331	  
mice were purchased from The Jackson Labs, Bar Harbor ME, USA. All colonies were housed and 332	  
bred in the SPF animal facility of Humanitas Clinical and Research Center in individually 333	  
ventilated cages. Il1r1-/-/Il1r8-/- mice were generated by crossing Il1r1-/- and Il1r8-/- mice. Il18-/-334	  
/Il1r8-/- were generated by crossing Il18-/- and Il1r8-/- mice. Mice were randomized based on sex, 335	  
age and weight.  336	  
Procedures involving animals handling and care were conformed to protocols approved by the 337	  
Humanitas Clinical and Research Center (Rozzano, Milan, Italy) in compliance with national (D.L. 338	  
N.116, G.U., suppl. 40, 18-2-1992 and N. 26, G.U. March 4, 2014) and international law and 339	  
policies (EEC Council Directive 2010/63/EU, OJ L 276/33, 22-09-2010; National Institutes of 340	  
Health Guide for the Care and Use of Laboratory Animals, US National Research Council, 2011). 341	  
The study was approved by the Italian Ministry of Health (approvals n. 43/2012-B, issued on the 342	  
08/02/2012 and n. 828/2015-PR, issued on the 07/08/2015). All efforts were made to minimize the 343	  
number of animals used and their suffering. In most in vivo experiments, the investigators were 344	  
unaware of the genotype of the experimental groups. Sample size was defined in order to detect 345	  
differences of 20% or grater between the groups (10% significance level and 80% power).	  346	  
 347	  
Human primary cells. Human peripheral mononuclear cells (PBMCs) were isolated from 348	  
peripheral blood of healthy donors, upon approval by Humanitas Research Hospital Ethical 349	  
Committee. PBMCs were obtained through a Ficoll density gradient centrifugation (GE Healthcare 350	  
Biosciences). NK cells were then purified by a negative selection, using a magnetic cell-sorting 351	  
technique according to the protocols given by the manufacturer (EasySep™ Human NK Cell 352	  
Enrichment Kit, Stem Cell Technology). Human monocytes were obtained from peripheral blood of 353	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healthy donors by two-step gradient centrifugation, first by Ficoll and then by Percoll (65% iso-354	  
osmotic; Pharmacia, Uppsala, Sweden). Residual T and B cells were removed from monocyte 355	  
fraction by plastic adherence. Monocytes were cultured in RPMI-1640 medium supplemented with 356	  
10% Fetal Bovine Serum (FBS), 1% L-Glutamine, 1% Pen/Strept and 100 ng/ml M-CSF 357	  
(Peprotech) for 7 days in order to generate resting macrophages. T and B cells were obtained from 358	  
peripheral blood of healthy donors using RosetteSep™ Human T Cell Enrichment Cocktail and 359	  
RosetteSep™ Human B Cell Enrichment Cocktail (Stem Cell Technology), following the 360	  
manufacturer's instructions. Neutrophils were enriched from Ficoll–isolated granulocytes, using 361	  
EasySep™ Human Neutrophil Enrichment Kit (StemCell Technologies), according to the 362	  
manufacturer’s instructions. 363	  
To analyse pluripotent haematopoietic stem cells (HSC) and NK cell precursors (NKP), human 364	  
Bone Marrow mononuclear cells were collected from Humanitas Biobank, upon approval by 365	  
Humanitas Research Hospital Ethical Committee (Authorization 1516, issued on February 26, 366	  
2016). Frozen samples were thawed and vitality was assessed by trypan blue and Aqua LIVE/Dead-367	  
405 nm staining (Invitrogen), before flow cytometry analysis. 368	  
Informed consent was obtained from all subjects. 369	  
 370	  
FACS analysis. Single-cell suspensions of BM, blood, spleen, lung and liver were obtained and 371	  
stained. Representative NK cell gating strategy is reported in Supplementary Fig. 1. 372	  
Foxp3/Transcription Factor Staining Buffer Set (eBioscience) was used for intracellular staining of 373	  
Granzyme B and Perforin. Cytofix/Cytoperm (BD Biosciences) was used for intracellular staining 374	  
of IFNγ. Liver ILC1 were identified as NK1.1+CD3-CD49a+CD49b- cells. Formalin 4% and 375	  
Methanol 100% were used for intracellular staining of IRAK4, pIRAK4, pS6 and JNK. The 376	  
following murine antibodies were used: CD45-BV605, -BV650 or -PerCp-Cy5.5 (Clone 30-F11); 377	  
CD45.1-BV650 (Clone A20); CD45.2-APC, -BV421 (Clone 104); CD3e-PerCP-Cy5.5 or -APC 378	  
(Clone 145-2C11); CD19-PerCP-Cy5.5, -eFluor450 (Clone 1D3); NK1.1-PE, -APC, -eFluor450 or 379	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–Biotin (Clone PK136); CD11b-BV421, -BV450, -BV785 (Clone M1/70); CD27-FITC or –APC-380	  
eFluor780 (Clone LG.7F9); CD4-FITC (Clone RM 4-5); CD8-PE (Clone 53-6.7); KLRG-1-BV421 381	  
(Clone 2F1); NKG2D-APC (Clone CX5); DNAM-1-APC (Clone 10E5); Ly49H-PECF594 (Clone 382	  
3D10); Granzyme B-PE (Clone NGZB); Perforin-PE (Clone eBioOMAK-D); IFNγ-Alexa700 or -383	  
APC (Clone XMG1.2); CD107a-Alexa647 (Clone 1D4B); FasL-APC (Clone MFL3);  Lineage Cell 384	  
Detection Cocktail-Biotin; Sca-1-FITC (Clone D7); CD117-PE or -Biotin (Clone 3C11); CD127-385	  
eFluor450 (Clone A7R34); CD135-APC or –Biotin (Clone A2F10.1); CD244-PE (Clone 2B4); 386	  
CD122-PE-CF594 (Clone TM-Beta1); CD49b-PE-Cy7 or Biotin (Clone DX5), CD49a-APC (Clone 387	  
Ha31/8), from BD Bioscience, eBioscience, BioLegend or Miltenyi Biotec. The following human 388	  
antibodies were used: CD56-PE (Clone CMSSB); CD3-FITC (Clone UCHT1); CD16-Pacific Blue 389	  
(Clone 3G8); CD34-PE-Vio770 (Clone AC136); CD117-BV605 (Clone 104D2); NKp46-BV786 390	  
(Clone 9E2/NKp46); CD45-PerCP (Clone 2D1); CD19-APC-H7 (Clone SJ25C1); CD14-APC-H7 391	  
(Clone M5E2); CD66b-APC-Vio770 (Clone REA306), from BD Bioscience, eBioscience or 392	  
Miltenyi Biotec. Biotinylated anti-hSIGIRR (R&D Systems) and Streptavidin-Alexa647 393	  
(Invitrogen™) were used to stain IL-1R8 in human cells. Human NKT cells were detected using 394	  
PE-CD1d tetramers loaded with αGalCer (ProImmune, Oxford, UK). Antibodies to detect protein 395	  
phosphorylation were as follows: p-IRAK4 Thr345/Ser346 (Clone D6D7), IRAK4, p-S6-Alexa647 396	  
Ser235/236 (Clone D57.2.2E); p-SAPK/JNK Thr183/Tyr185 (Clone 81E11), from Cell Signaling 397	  
Technology. A Goat	  anti-Rabbit-Alexa647 secondary antibody (Invitrogen™) was used to stain p-398	  
IRAK4, IRAK4 and p-SAPK/JNK. Results are reported as mean fluorescence intensity (MFI) 399	  
normalized on isotype control or fluorescence minus one (FMO). Cell viability was determined by 400	  
Aqua LIVE/Dead-405 nm staining (Invitrogen) or Fixable Viability Dye (FVD) eFluor® 780 401	  
(eBioscience), negative cells were considered viable. Cells were analyzed on LSR Fortessa or 402	  
FACSVerse (BD Bioscience). Data were analyzed with FlowJo software (Treestar).  403	  
 404	  
Quantitative PCR. Total RNA was extracted using Trizol reagent (Invitrogen) following the 405	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manufacturer’s recommendations. RNA was further purified using miRNeasy RNA isolation kit 406	  
(QIAGEN) or Direct-zol™ RNA MiniPrep Plus (Zymo Research). cDNA was synthesized by 407	  
reverse transcription using High Capacity cDNA archive kit (Applied Biosystems) and quantitative 408	  
real-time PCR was performed using the SybrGreen PCR Master Mix (Applied Biosystems) in a 409	  
CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad). PCR reactions were carried out with 410	  
10 ng of DNA. Data were analyzed with the Δ2CT method. Data were normalized based on 411	  
GAPDH, βactin or 18S expression, as indicated, determined in the same sample. Analysis of all 412	  
samples was performed in duplicate. Primers were designed according to the published sequences 413	  
and listed as follows: s18/S18: forward 5'-ACT TTC GAT GGT AGT CGC CGT-3', reverse 5'- 414	  
CCT TGG ATG TGG TAG CCG TTT-3'; Gapdh/GAPDH: forward 5'-GCA AAG TGG AGA TTG 415	  
TTG CCA T-3', reverse 5'-CCT TGA CTG TGC CGT TGA ATT T-3'; βactin/βACTIN: forward 5'-	  416	  
CCC AAG GCC AAC CGC GAG AAG AT-3', reverse 5'-	  GTC CCG GCC AGC CAG GTC CAG 417	  
-3'; il1r8: forward 5'-	  AGA GGT CCC AGA AGA GCC AT-3', reverse 5'-	  AAG CAA CTT CTC 418	  
TGC CAA GG-3'; IL1R8: forward 5'-	  ATG TCA AGT GCC GTC TCA ACG -3', reverse 5'-	  GCT 419	  
GCG GCT TTA GGA TGA AGT-3'; il1r1: forward 5’- TGC TGT CGC TGG AGA TTG AC -3’, 420	  
reverse 5’- TGG AGT AAG AGG ACA CTT GCG AA -3’; il1r2: forward 5’- AGT GTG CCC 421	  
TGA CCT GAA AGA -3’, reverse 5’- TCC AAG AGT ATG GCG CCC T -3’; il1r3: forward 5’- 422	  
GGC TGG CCC GAT AAG GAT -3’, reverse 5’- GTC CCC AGT CAT CAC AGC G -3’; il1r4: 423	  
forward 5’- GAA TGG GAC TTT GGG CTT TG -3’, reverse 5’- GAC CCC AGG ACG ATT TAC 424	  
TGC -3’; il1r5: forward 5’- GCT CGC CCA GAG TCA CTT TT -3’, reverse 5’- GCG ACG ATC 425	  
ATT TCC GAC TT -3’; il1r6: forward 5’- GCT TTT CGT GGC AGC AGA TAC -3’, reverse 5’- 426	  
CAG ATT TAC TGC CCC GTT TGT T -3’; 16S: forward 5’- AGA GTT TGA TCC TGG CTC 427	  
AG -3’, reverse 5’- GGC TGC TGG CAC GTA GTT AG -3’.  428	  
 429	  
Purification of murine leukocytes. Splenic NK cells and bone marrow neutrophils were MACS 430	  
enriched according to manufacturer’s instructions (Miltenyi Biotec). Purity of NK cells was about 431	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90% as determined by FACS. Purity of neutrophils was ≥ 97.5%. NK cells were stained (CD45-432	  
BV650, NK1.1-PE, CD3e-APC, CD11b-BV421, CD27-FITC) and sorted on a FACSAria cell sorter 433	  
(BD Bioscience) to obtain high purity NK cells and NK cell populations (CD11blowCD27low, 434	  
CD11blowCD27high, CD11bhighCD27high and CD11bhighCD27low). Splenic B and T lymphocytes were 435	  
stained (CD45-PerCP, CD3e-APC, CD4-FITC, CD8-PE, CD19-eFluor450) and sorted. Purity of 436	  
each population was ≥ 98%. Resulting cells were processed for mRNA extraction or used for 437	  
adoptive transfer or co-culture experiments. In vitro-derived macrophages were obtained from bone 438	  
marrow total cells. Bone marrow cells were cultured in RPMI-1640 medium supplemented with 439	  
10% Fetal Bovine Serum (FBS), 1% L-Glutamine, 1% Pen/Strept and 100 ng/ml M-CSF 440	  
(Peprotech) for 7 days in order to generate resting macrophages. Bone marrow cells were cultured 441	  
in RPMI-1640 medium supplemented with 10% Fetal Bovine Serum (FBS), 1% L-Glutamine, 1% 442	  
Pen/Strept and 20 ng/ml GM-CSF (Peprotech) for 7 days in order to generate DCs. 443	  
 444	  
Confocal microscopy: Murine splenic NK cells were MACS enriched, let adhere on poly-D-Lysine 445	  
(Sigma-Aldrich) coated coverslips, fixed with 4% PFA, permeabilized with 0.1% Triton X-100, 446	  
incubated with blocking buffer (5% normal donkey serum (Sigma-Aldrich), 2% BSA, 0.05% 447	  
Tween). Cells were then stained with biotin-conjugated goat polyclonal anti-SIGIRR antibody or 448	  
biotin-conjugated normal goat IgG as control (both R&D Systems) (10µg/ml) followed by Alexa 449	  
Fluor 488–conjugated donkey anti-goat IgG antibody (Molecular Probes) and DAPI (Invitrogen). 450	  
Coverslips were mounted with the antifade medium FluorPreserve Reagent (EMD Millipore) and 451	  
analyzed with an Olympus Fluoview FV1000 laser scanning confocal microscope with oil 452	  
immersion lens 40× (N.A.1.3). 453	  
 454	  
Stimulated emission depletion (STED) microscopy  455	  
Human NK cells were enriched and let adhere on poly-D-Lysine (Sigma-Aldrich) coated coverslips, 456	  
stimulated with IL-18 (50 ng/ml; 1 min, 5 min, 10 min), fixed with 4% PFA, incubated with 5% 457	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normal donkey serum (Sigma-Aldrich), 2% BSA, 0.05% Tween in PBS2+ (pH 7.4) (blocking 458	  
buffer), and then with biotin-conjugated goat polyclonal anti-human IL-1R8 antibody or biotin-459	  
conjugated normal goat IgG (all from R&D Systems) and mouse monoclonal anti-IL-18Rα (Clone 460	  
70625; R&D System) or mouse IgG1 (Invitrogen), all diluted at 5µg/ml in blocking buffer, 461	  
followed by Alexa Fluor 488– conjugated donkey anti-goat IgG antibody and Alexa Fluor 555 462	  
donkey anti-mouse IgG antibody (both from Molecular Probes). Mowiol was used as mounting 463	  
medium. STED xyz images were acquired in a unidirectional mode with a Leica SP8 STED3X 464	  
confocal microscope system. Alexa Fluor 488 was excited with a 488nm Argon Laser and emission 465	  
collected from 505 to 550 nm applying a gating between 0.4 to 7ns to avoid collection of reflection 466	  
and autofluorescence. Alexa Fluor 555 was excited with a 555/547nm-tuned white light laser 467	  
(WLL) and emission collected from 580 to 620 nm. Line sequential acquisition was applied to 468	  
avoid fluorescence overlap. The 660nm CW-depletion laser (80% of power) was used for both 469	  
excitations. Images were acquired with Leica HC PL APO 100x/1.40 oil STED White objective at 470	  
572.3mAU. CW-STED and gated CW-STED were applied to Alexa-488nm and Alexa Fluor 555, 471	  
respectively. Collected images were de-convolved with Huygens Professional software. 472	  
 473	  
3′-mRNA Sequencing and Analysis 474	  
Splenic NK cells  (from 6 mice per genotype and pooled in pairs) were purified as described above 475	  
and stimulated with IL-18 (MBL) (20 ng/ml for 4 h). RNA was prepared as described above. The 476	  
QuantSeq 3′mRNA-seq Library Prep Kit for Illumina (Lexogen) was used to generate libraries, 477	  
which were sequenced on the NextSeq (Illumina; 75 bp PE).  The fastq sequence files were 478	  
assessed using the fastqc program. The reads were first trimmed using bbduk in the bbmap suite of 479	  
software32 to remove the first 12 bases and a contaminant kmer discovery length of 13 was used for 480	  
contaminant removal. Regions of length 20 or above with average quality of less than 10 were 481	  
trimmed from the end of the read. The reads were then trimmed to remove trailing polyG and polyA 482	  
runs using cutadapt33 and the quality of the remaining reads reassessed with fastqc. The trimmed 483	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reads were aligned to the mm10 genomic reference and reads assigned to features in the mm10 484	  
annotation using the STAR program34. Differential expression analysis was performed using the 485	  
generalized linear model (GLM) functions in the R/bioconductor35 edgeR package36 with TMM 486	  
normalization. Gene set analysis was performed using the romer37 function in the R/bioconductor 487	  
package limma38. Metascape (http://metascape.org) was used to enrich genes for GO biological 488	  
processes, KEGG Pathway and Reactome Gene Sets.  489	  
 490	  
Measurement of cytokines: BD Cytometric Bead Array (CBA) mouse inflammation kit (BD) or 491	  
Duoset ELISA kits (R&D System) were used to measure cytokines.  492	  
 493	  
In vitro functional assays. Total murine splenocytes or enriched murine or human NK cells were 494	  
cultured in RPMI-1640 medium supplemented with 10% Fetal Bovine Serum (FBS) 1% L-495	  
Glutamine, 1% Pen/Strept and treated with IL-2, IL-12, IL-15 (Peprotech), IL-18 (MBL), IL-1β 496	  
(Peprotech) and PMA-Ionomycin (Sigma-Aldrich), as specified. FasL expression was evaluated 497	  
upon treatment for 45 minutes with IL-18 (50 ng/ml), IL-15 (50 ng/ml), IL-2 (20 ng/ml) and IL-12 498	  
(10 ng/ml). IFNγ production was analysed upon 16 hours of treatment with IL-12 (20 ng/ml) and 499	  
IL-18 (20 ng/ml) or IL-1β (20 ng/ml), by intracellular staining using BD Cytofix/CytopermTM 500	  
Fixation/Permeabilization Kit, following the manufacturer's instructions, or by ELISA. Granzyme B 501	  
and Perforin intracellular staining was performed upon 18 hours of stimulation with IL-12 (10 502	  
ng/ml), IL-15 (10 ng/ml) and IL-18 (50 ng/ml), using Foxp3/Transcription Factor Staining Buffer 503	  
Set (eBioscience). CD107a-Alexa647 antibody was added during the 4-hour culture and analysed 504	  
by flow cytometry.  BD GolgiPlugTM (containing Brefeldin) and BD GolgiStopTM (containing 505	  
Monensin) were added 4 hours prior to intracellular staining. PMA (50 ng/ml)-	   Ionomycin (1 506	  
µg/ml) were added 4 hours prior to intracellular staining, when specified. 507	  
NK-DC co-culture experiments were performed as previously described39. DCs were treated with 508	  
LPS from Escherichia coli O55:B5 (Sigma-Aldrich; 1µg/ml) or CpG ODN 1826 (Invivogen; 509	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3µg/ml) and with anti-mIL-18 neutralizing antibody (BioXCell, Clone YIGIF74-1G7; 5µg/ml) or 510	  
Rat Isotype Control (BioXCell, Clone 2A3). 511	  
IFNγ and CD107a expression upon viral infection was analyzed by flow cytometry upon 4-hour 512	  
treatment with BD GolgiPlugTM, BD GolgiStopTM and IL-2 (500U/ml).  513	  
Phosphorylation of IRAK4, S6 and JNK was analyzed upon 15-30 minutes of stimulation with IL-514	  
18 (10 ng/ml). 515	  
 516	  
Human primary NK cell transfection: Human NK cells were enriched from peripheral blood of 517	  
healthy donors and transfected with Dharmacon™ Acell™ siRNA (GE Healthcare) using Accell™ 518	  
delivery medium (GE Healthcare), following the manufacturer’s instructions. 1 µM SIGIRR-519	  
specific siRNA (On-Target Plus; Dharmacon, GE Healthcare) comprised 250 nM of the four 520	  
following antisense sequences: I, AGU UUC GCG AGC CGA GAU CUU; II, UAC CAG AGC 521	  
AGC ACG UUG AUU; III, UGA CCC AGG AGU ACU CGU GUU; IV, CUU CCC GUC GUU 522	  
UAU CUC CUU (all 5’ to 3’). 523	  
  524	  
Generation of bone marrow chimeras. Il1r8-/- and Il1r8+/+ mice were lethally irradiated with a 525	  
total dose of 900 cGy. 2 h later, mice were injected in the retro-orbital plexus with 4x106 nucleated 526	  
bone marrow cells obtained by flushing of the cavity of freshly dissected femurs from wild type or 527	  
Il1r8-/- donors. Competitive bone marrow chimeric mice were generated by reconstituting recipient 528	  
mice with 50% CD45.1 Il1r8+/+ and 50% CD45.2 Il1r8-/- bone marrow cells. Recipient mice 529	  
received gentamycin (0.8 mg/ml in drinking water) starting 10 days before irradiation and for 2 530	  
weeks after irradiation. NK cells of chimeric mice were analyzed 8 weeks after bone marrow 531	  
transplantation.  532	  
 533	  
Depletion and blocking experiments. Mice were treated intraperitoneally with 200 µg of specific 534	  
mAbs (Mouse anti-NK1.1, Clone PK136; Mouse Isotype Control, Clone C1.18.4; Rat anti-mIL-18, 535	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Clone YIGIF74-1G7; Rat Isotype Control, Clone 2A3; Rat anti-IFNγ, Clone XMG1.2; Rat IgG1 536	  
HRPN; Mouse anti-IL-17A, Clone 17F3; Mouse Isotype Control, Clone MOPC-21; Rat anti-537	  
CD4/CD8, Clone GK1.5/YTS; Rat Isotype Control, Clone LTF-2 (all from BioXCell)) and then 538	  
with 100 µg once (anti-NK1.1) or three times (anti-IL-18, anti-IFNγ, anti-IL-17A, anti-CD4/CD8) a 539	  
week for the entire duration of the experiment.  540	  
 541	  
Microflora depletion. 6-week-old mice were treated every day for 5 weeks by oral gavage with a 542	  
cocktail of antibiotics [ampicillin (Pfizer) 10 mg/ml, vancomycin (PharmaTech Italia) 10 mg/ml, 543	  
metronidazol (Società Prodotti Antibiotici) 5 mg/ml and neomycin (Sigma-Aldrich) 10 mg/ml]. 544	  
Control mice were treated with drinking water. A gavage volume of 10 ml/kg body weight was 545	  
delivered with a stainless steel tube without prior sedation of mice. DNA was isolated from 546	  
bacterial fecal pellets with PowerSoil® DNA Isolation Kit (MO BIO Laboratories, Inc.) and 547	  
quantified by spectrophotometry at 260 nm. PCR was performed with 10 ng of DNA using the 548	  
SybrGreen PCR Master Mix (Applied Biosystems) in a CFX96 Touch™ Real-Time PCR Detection 549	  
System (Bio-Rad). Data were analyzed with the Δ2CT method (Applied Biosystems, Real-Time 550	  
PCR Applications Guide).  551	  
 552	  
Cancer models. Mice were injected intraperitoneally (i.p.) with 25 mg/kg of diethylnitrosamine 553	  
(DEN, Sigma) at 15 days of age. Mice were sacrificed 6-8-10-12 months later, to analyze liver 554	  
cancer. Liver cancer score was based on number and volume of lesions (0: no lesions; 1: lesion 555	  
number<3, or lesion dimension <3mm; 2: lesion number<5, or lesion dimension <5mm; 3: lesion 556	  
number<10, or lesion dimension <10mm; 4: lesion number<15, or lesion dimension <10mm; 5: 557	  
lesion number>15, or lesion dimension >10mm). Lung metastasis experiments were performed 558	  
injecting i.m. the 3-MCA derived mycoplasma-free sarcoma cell line MN/MCA1 (105 cells/mouse 559	  
in 100 µl PBS)40. Primary tumor growth was monitored twice weekly, and lung metastases were 560	  
assessed by in vivo imaging and by macroscopic counting at sacrifice 25 days after injection. Liver 561	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metastases were generated by injecting intrasplenically 1.5x105 mycoplasma-free colon carcinoma 562	  
cells (MC38) 21. Mice were sacrificed 12 days after injection and liver metastasis were counted 563	  
macroscopically. MC38 cells were received from ATCC just before use. MN/MCA1 cells were 564	  
authenticated morphologically by microscopy in vitro and by histology ex vivo. Tumor size limit at 565	  
which mice were sacrificed was based on major diameter (≤ 2cm). 566	  
 567	  
Viral infections 568	  
Mice were injected intravenously (i.v.) with 5×105 PFU of the tissue culture (TC)-grown virus in 569	  
PBS. Bacterial artificial chromosome (BAC)-derived MCMV strain MW97.01 has been previously 570	  
shown to be biologically equivalent to MCMV strain Smith (VR-1399) and is hereafter referred to 571	  
as wild-type (WT) MCMV41. Mice were sacrificed 1.5 and 4.5 days post infection and viral titer 572	  
was assessed by plaque assay, as previously described42,43. Newborn mice were infected i.p. with 573	  
2000 PFU of the MCMV strain MW97.01 and sacrificed at day 7 post infection. Viral titer was 574	  
assessed by plaque assay, as previously described42,43. 575	  
 576	  
Adoptive transfer. 106 Il1r8+/+ or Il1r8-/- sorted NK cells were injected i.v. in wild type adult mice 577	  
5 hours before MN/MCA or MC38 injection, or i.p. in newborn mice 48 hours after MCMV 578	  
injection. Adoptively transferred NK cell engraftment, proliferative capacity and functionality 579	  
(IFNγ production and degranulation after ex vivo stimulation) were assessed 3 and 7 days after 580	  
injection. 581	  
 582	  
In vivo proliferation was measured using Click-iT® Edu Flow Cytometry Assay Kit (Invitrogen). 583	  
Edu was injected i.p. (0.5 mg/mouse), mice were sacrificed 24 hours later and cells were stained 584	  
following the manufacturer’s instructions and analyzed by flow cytometry.  585	  
 586	  
Immunohistochemistry. Liver frozen tissues were cut at 8 mm and then fixed with 4% PFA. 587	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Endogenous peroxidases were blocked with 0.03% of H2O2 for 5 min and unspecific binding sites 588	  
were blocked with PBS + 1% FBS for 1h. Tissues were stained with polyclonal goat anti mouse 589	  
NKp46/NCR1 (R&D System) and goat on mouse HRP polymer kit (GHP516, Biocare Medical) 590	  
was used as secondary antibody. Reactions were developed with 3,3’-Diaminobenzidine (DAB) 591	  
(Biocare Medical) and then slides were counterstained with hematoxylin. Slides were mounted with 592	  
eukitt (Sigma-Aldrich). 20X images were analyzed with cell^F software (Olympus). 593	  
 594	  
In vivo Imaging. After feeding with AIN-76A alfalfa-free diet (Mucedola srl, Italy) for two weeks, 595	  
to reduce fluorescence background, mice were intravenously (i.v.) injected with XenoLight 596	  
RediJect 2-DeoxyGlucosone (DG) (PerkinElmer) and 24 hours later 2-DG fluorescence was 597	  
measured using Fluorescence Molecular Tomography system (FMT 2000, Perkin Elmer). Acquired 598	  
images were subsequently analyzed with TrueQuant 3.1 analysis software (Perkin Elmer). 599	  
 600	  
Data availability: The data discussed in this publication have been deposited in NCBI Gene 601	  
Expression Omnibus and are accessible through GEO Series accession number GSEXXXXX, or 602	  
from the corresponding author. Figure source data are provided. 603	  
 604	  
Statistical analysis. For animal studies, sample size was defined on the basis of past experience on 605	  
cancer and infection models, in order to detect differences of 20% or grater between the groups 606	  
(10% significance level and 80% power). Values were expressed as mean ± SEM or median of 607	  
biological replicates, as specified. One-way ANOVA or Kruskal-Wallis test were used to compare 608	  
multiple groups. Two-sided unpaired Student’s t test was used to compare unmatched groups with 609	  
Gaussian distribution and Welch’s correction was applied in case of significantly different variance. 610	  
Mann-Whitney test was used in case of non-Gaussian distribution. ROUT test was applied to 611	  
exclude outliers. p≤0.05 was considered significant. Statistics were calculated with GraphPad Prism 612	  
version 6, GraphPad Software.  613	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 614	  
Statistics and reproducibility 615	  
Figure 1: a, n=4 (B cells), n=5 (NKT cells), n=9 (T cells) , n=10 (NK cells) donors; b, n=5 donors; 616	  
c, n=8 (NK cells) or n=4 (T cells) or n=3 (other leukocytes) mice; d, n=5 mice. b, representative 617	  
experiment out of 6 performed. a, c, d, one experiment performed.  618	  
Figure 2: a, b, n=8 or n=7 (spleen, Il1r8+/+ liver) or n=6 (Il1r8-/- liver) mice; c, n= 6 mice; d, n=9 619	  
(Il1r8+/+) or n=6 (Il1r8-/-) mice; e, n=5 mice; f, n=6 mice; g, n=4 mice; h, n=5 mice; i, n=10 wells; j, 620	  
n=4 (IRAK4), n=6 or n=5 (S6 Il1r8-/-) or n=7 (JNK Il1r8-/-) mice; k, n=3 mice; l, n=9 healthy 621	  
donors; m, n=4 healthy donors. Representative experiments out of 3 (a, b), 5 (c), 2 (d, j), 4 (e) 622	  
performed. f-m one experiment performed. 623	  
Figure 3: a, n= 8, 10, 11, 13, 14 mice; b, c, n=6 mice; d, n=10, 12, 13 mice; e, n=10, 11 mice; f, 624	  
n=5, 6, 7 mice; g, n=9, 10 mice; h, n=5, 6 mice; i, n= 9, 10 or 12 mice; j, n=6 mice. Representative 625	  
experiments out of 6 (e), 3 (a), 2 (d, f, g, h, i). b, c, j, one experiment performed.  626	  
Figure 4: a,b, n=5 mice; c, n=6, n=9 mice; d, n=4 mice. a, two experiments were performed; b-d, 627	  
one experiment was performed. 628	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Extended Data, Figures 663	  
 664	  
Extended Data Figure 1. Expression of IL-1R8 in human and murine NK cells 665	  
(a, b) IL-1R8 mRNA (a) expression in human primary NK cells, compared with T and B cells, 666	  
neutrophils, monocytes and in vitro-derived macrophages (a) and in human primary NK cell 667	  
maturation stages (CD56brCD16-, CD56brCD16+, CD56dimCD16+), and in the CD56dimCD16- subset 668	  
(b).  669	  
(c) Representative FACS plot of human NK cell subsets and histograms of IL-1R8 expression in 670	  
NK cell subsets. 671	  
(d) IL-1R8 protein expression in human bone marrow precursors and mature cells.  672	  
(e) IL-1 receptor family members (Il1r1, Il1r2, Il1r3, Il1r4, Il1r5, Il1r6, Il1r8) mRNA expression in 673	  
murine primary NK cells isolated from the spleen.  674	  
(f) IL-1R8 protein expression in murine NK cells by confocal microscopy. Magnification bar: 675	  
10µm. 676	  
(g) Representative FACS plot of murine NK cell subsets. 677	  
 678	  
(a, b, d) *p < 0.05, **p < 0.01, ***p < 0.001 One-way ANOVA. Mean ± SEM.  679	  
a, n=6 (NK and B cells) or n=4 donors; b, n=5 donors; d, n=4 donors; e, n=2 mice; f, representative 680	  
images out of four collected per group. 681	  
a, b, d, e, f, one experiment performed.  682	  
  683	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Extended Data Figure 2. Phenotypic analysis of Il1r8-/- NK cells. 684	  
 (a, b) Representative FACS plot of murine NK cell subsets in Il1r8+/+ and Il1r8-/- mice (a) and 685	  
histograms of KLRG1 expression in NK cells. 686	  
(c, d) NK absolute number and NK cell subsets (DN, CD11blow, DP and CD27low) in bone marrow, 687	  
spleen and blood of Il1r8+/+ and Il1r8-/- newborn mice at 2 (c) and 3 (d) weeks of age.  688	  
(e) Frequency of bone marrow precursors in Il1r8+/+ and Il1r8-/- mice. 689	  
(f) NKG2D, DNAM-1 and LY49H expression in peripheral NK cells and NK cell subsets of 690	  
Il1r8+/+ and Il1r8-/- mice. 691	  
(g) Frequency of splenic Perforin+ NK cell subsets upon stimulation in Il1r8+/+ and Il1r8-/- mice.  692	  
(h and i) Peripheral NK cell absolute number (h) and CD27low NK cell frequency (i) in bone 693	  
marrow chimeric mice upon reconstitution (9 weeks). 694	  
(j and k) Peripheral NK cell (j) and NK cell subset (k) frequency in competitive chimeric mice 695	  
transplanted with 50% of Il1r8+/+ CD45.1 cells and 50% of Il1r8-/- CD45.2 cells upon reconstitution 696	  
(9 weeks). Upon reconstitution a defective engraftment (12% instead of 50% engraftment) of Il1r8-/- 697	  
stem cells was observed in competitive conditions.  698	  
(l) IFNγ production by Il1r8+/+ and Il1r8-/- NK cells upon co-culture with LPS- or CpG-primed 699	  
Il1r8+/+ and Il1r8-/- DCs. 700	  
(c-l) *p < 0.05, **p < 0.01, ***p < 0.001 between selected relevant comparisons, two-tailed 701	  
unpaired Student’s t test. Centre values and error bars represent mean ± SEM. At least 5 animals per 702	  
group were used. c, d: 3 pooled experiments. e-l: one experiment was performed.  703	  
  704	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Extended Data Figure 3. Mechanism of IL-1R8-dependent regulation of NK cells 705	  
 (a) Splenic CD27low NK cell frequency in wild type, Il1r8-/-, Il18-/-, and Il18-/-/Il1r8-/- mice. 706	  
(b) Peripheral CD27low NK cell frequency in wild-type, Il1r8-/-, Il1r1-/- and Il1r8-/-Il1r1-/- mice (left) 707	  
and IFNγ production by splenic NK cells after IL-12 and IL-1β or IL-18 stimulation (right). 708	  
(c, d) Splenic CD27low NK cell frequency in Il1r8+/+ and Il1r8-/- mice upon commensal flora 709	  
depletion (c) and breeding in co-housing conditions (d).  710	  
 (e) STED microscopy of human NK cells stimulated with IL-18. Magnification bar: 2µm. 711	  
(a-d) *p < 0.05, **p < 0.01, ***p < 0.001 between selected relevant comparisons, two-tailed 712	  
unpaired Student’s t test, or ANOVA; Centre values and error bars represent mean ± SEM. a, n= 3, 713	  
5, or 6 mice; at least 5 animals per group were used (b-d). a-d: one experiment was performed. e: 714	  
representative images out of three collected from two donors.  715	  
 716	  
Extended Data Figure 4. RNA-seq analysis of Il1r8+/+ and Il1r8-/- NK cells. 717	  
(a) Metascape analysis of enriched gene pathways of resting and IL-18-activated Il1r8+/+ and Il1r8-/- 718	  
NK cells. 719	  
See also Extended data, Table 1 and data deposited in NCBI Gene Expression Omnibus accessible 720	  
through GEO Series accession number GSEXXXXX. 721	  
 722	  
Extended Data Figure 5. NK cell-mediated resistance to HCC and metastasis in IL-1R8-723	  
deficient mice. 724	  
(a) Macroscopic score of liver lesions in female Il1r8+/+ and Il1r8-/- mice 6, 10 and 12 months after 725	  
DEN injection.  726	  
(b) HCC incidence in Il1r8+/+ and Il1r8-/- female and male mice. 727	  
(c) Frequency of IFNγ+ NK cells in spleen of Il1r8+/+ and Il1r8-/- tumor bearing mice. 728	  
(d) Macroscopic score of liver lesions in female Il1r8+/+ and Il1r8-/- mice upon NK cell depletion.  729	  
(e) 2-DG quantification in lungs of Il1r8+/+ and Il1r8-/- tumor bearing mice upon NK cell depletion. 730	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(f) Primary tumor growth in Il1r8+/+ and Il1r8-/- mice (25 days after MN/MCA1 cell line injection). 731	  
(g) Number of lung metastasis in Il1r8+/+ and Il1r8-/- MN/MCA1 sarcoma bearing mice upon IFNγ 732	  
or IL-18 neutralization.  733	  
(h) Volume of lung metastases in Il1r8+/+ and Il1r8-/- MN/MCA1-bearing mice upon depletion of 734	  
IL-17A or CD4+/CD8+ cells. 735	  
(i) Number of lung metastases in Il1r8+/+ and Il1r8-/-, Il1r1-/-, Il1r1-/-/Il1r8-/- MN/MCA1-bearing 736	  
mice. 737	  
(j) Number of liver metastasis in Il1r8+/+, Il1r8-/-, Il18-/-, Il18-/-Il1r8-/- MC38 colon carcinoma 738	  
bearing mice. 739	  
(k) Il1r8+/+ and Il1r8-/- NK cell absolute number three or 7 days after adoptive transfer. 740	  
(l) In vivo Il1r8+/+ and Il1r8-/- NK cell proliferation three days after adoptive transfer. 741	  
(m) Ex vivo IFNγ production and degranulation upon 4-hour stimulation with PMA-Ionomycin, IL-742	  
12 and IL-18 in adoptively transferred Il1r8+/+ and Il1r8-/- NK cells. 743	  
 (n) Volume of lung metastasis of Il1r8+/+ MN/MCA1 sarcoma bearing mice after adoptive transfer 744	  
of Il1r8+/+ and Il1r8-/- NK cells. 745	  
(a, c-e, g-j, m-n) *p < 0.05, **p < 0.01, ***p < 0.001 between selected relevant comparisons, two-746	  
tailed unpaired Student’s t test or Mann-Whitney test. #p<0.05, ##p<0.01, Kruskal-Wallis and 747	  
Dunn's multiple comparison test. Centre values and error bars represent mean ± SEM. a, n=9, 10, 748	  
11, 18, 21 mice; b, n=8-21 mice; c, n=6 mice; d, n= 10, 12, 13 mice; e, n=4 (Il1r8-/- isotype) or n=5; 749	  
f, n=10; g, n=6, 7, 9, 10 mice; h, n=5, 6, 12 mice; i, n=6, 8, 10 mice; j, n=4, 5, 7 mice; k, l, m, n=3 750	  
mice; n, n=9, 10, 12 mice. Representative experiment out of 3 (a, b), 2 (d), 6 (f), or one (c, e, g-n) 751	  
experiment performed.  752	  
 753	  
Extended Data Figure 6. NK cell-mediated antiviral resistance in IL-1R8-deficient mice 754	  
(a) Cytokine serum levels in Il1r8+/+ and Il1r8-/- infected mice (1.5 and 4.5 days post infection). 755	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*p < 0.05, **p < 0.01, ***p < 0.001, unpaired Student’s t test. Centre values and error bars 756	  
represent mean ± SEM.  n=5 mice. One experiment was performed. 757	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